Latest Breaking News On - Chongbo zhao - Page 3 : comparemela.com

argenx and Zai Lab Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China

argenx and Zai Lab Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Noord hollandHong kongUnited statesTim van hauwermeirenErin murphyGroup of huashan rare disease centerZai lab nasdaqImmunology innovation programZai labZai lab announce approvalHuashan hospital affiliated to fudan universityChina national medical products administrationNational healthcare security administrationDepartment of neurologyZai lab limited nasdaqNational reimbursement drug list

Zai Lab and argenx Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China

First-and-only approved FcRn antagonist for gMG patients by NMPA 68% of anti-AChR antibody positive gMG patients treated with VYVGART were responders on the Myasthenia Gravis Activities of Daily.

United kingdomHong kongUnited statesShaun maccoun xiaoyu chenTim van hauwermeirenChristine chiou lina zhangGroup of huashan rare disease centerZai lab forwardExchange commissionZai labDepartment of neurologyChina national medical products administrationNational reimbursement drug listNational healthcare security administrationImmunology innovation programHuashan hospital affiliated to fudan university

Harbour BioMed Announces Biologics License Application Acceptance of Batoclimab for Treatment of Generalized Myasthenia Gravis by NMPA

/PRNewswire/ Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization.

United kingdomJingsong wangNational medical products administrationBiomed the companyBiologics license applicationHarbour biomedChongbo zhaoHuashan hospitalFudan universityGreater chinaGeneralized myasthenia gravis

Harbour BioMed Announces Positive Topline Results from Phase III Trial of Batoclimab for Treatment of Generalized Myasthenia Gravis

/PRNewswire/ Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization.

United kingdomJingsong wangHarbour biomed the companyHarbour biomedChongbo zhaoHuashan hospitalFudan universityGreater chinaGeneralized myasthenia gravis

Zai Lab Announces Acceptance by China s NMPA of the BLA for Efgartigimod for Patients with Generalized Myasthenia Gravis

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

United kingdomUnited statesHarald reinhartJennifer chang xiaoyu chenAlina zhangHuashan hospital affiliated to fudan universityDepartment of neurologyGroup of huashan rare disease centerZai labDrug administrationZai lab limitedExchange commissionChina national medical products administrationJapan ministry of healthHead of global developmentZai lab forward